Cargando…

The role of PD-L1 in the radiation response and clinical outcome for bladder cancer

Identification of potential factors that can stratify a tumor’s response to specific therapies will aid in the selection of cancer therapy. The aim was to highlight the role of programmed cell death 1 ligand 1 (PD-L1) in bladder cancer. In this study, 92 of muscle-invasive bladder cancers and 28 of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chun-Te, Chen, Wen-Cheng, Chang, Ying-Hsu, Lin, Wei-Yu, Chen, Miao-Fen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726250/ https://www.ncbi.nlm.nih.gov/pubmed/26804478 http://dx.doi.org/10.1038/srep19740

Ejemplares similares

Impact of CD44 expression on radiation response for bladder cancer
por: Wu, Chun-Te, et al.
Publicado: (2017)

Thrombomodulin expression regulates tumorigenesis in bladder cancer
por: Wu, Chun-Te, et al.
Publicado: (2014)

The role of IL-6 in the radiation response of prostate cancer
por: Wu, Chun-Te, et al.
Publicado: (2013)

The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression
por: Chen, Miao-Fen, et al.
Publicado: (2016)

DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer
por: Wu, Chun-Te, et al.
Publicado: (2015)

The Significance of Neutrophil-to-Lymphocyte Ratio and Combined Chemoradiotherapy in Patients Undergoing Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
por: Wu, Chun-Te, et al.
Publicado: (2020)

Effect of 1α,25-Dihydroxyvitamin D3 on the Radiation Response in Prostate Cancer: Association With IL-6 Signaling
por: Wu, Chun-Te, et al.
Publicado: (2021)

Cystectomy for bladder cancer in elderly patients is not associated with increased 30- and 90-day mortality or readmission, length of stay, and cost: propensity score matching using a population database
por: Lin, Wei-Yu, et al.
Publicado: (2018)

IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer
por: Chen, Miao-Fen, et al.
Publicado: (2013)

Correction: IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer
por: Chen, Miao-Fen, et al.
Publicado: (2016)

The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation
por: Wu, Chun-Te, et al.
Publicado: (2018)

Perioperative Complications and Oncologic Outcomes after Radical Cystectomy in End-Stage Renal Disease Patients with Bladder Cancer Obtained Using a Standardized Reporting System
por: Liu, Yu-Liang, et al.
Publicado: (2022)

Androgen deprivation modulates the inflammatory response induced by irradiation
por: Wu, Chun-Te, et al.
Publicado: (2009)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
por: Yi, Ruibin, et al.
Publicado: (2022)

The Predictive Role of Prostate-Specific Antigen Changes Following Transurethral Resection of the Prostate for Patients with Localized Prostate Cancer
por: Wu, Chun-Te, et al.
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide
por: Lee, Gilbert Aaron, et al.
Publicado: (2021)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
por: Sun, Nai-Yun, et al.
Publicado: (2019)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
por: de Jong, Florus C., et al.
Publicado: (2021)

Identification and Mechanism of the PD-1/PD-L1 Genomic Signature SORL1 as Protective Factor in Bladder Cancer
por: Xu, Yajing, et al.
Publicado: (2021)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer
por: Russo, Giorgio Ivan, et al.
Publicado: (2022)

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
por: Hsu, Jung-Mao, et al.
Publicado: (2018)

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
por: Liu, Chunnan, et al.
Publicado: (2022)

The effect of hypoxia on PD-L1 expression in bladder cancer
por: Smith, Vicky, et al.
Publicado: (2021)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
por: Wu, Chiao-En, et al.
Publicado: (2020)

S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8(+) T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
por: Li, Huihuang, et al.
Publicado: (2023)

Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor
por: Huang, Liang-Kang, et al.
Publicado: (2023)

PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy
por: Pichler, Renate, et al.
Publicado: (2017)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Yin, Zi, et al.
Publicado: (2021)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

Immunosuppressive Effect of Litsea cubeba L. Essential Oil on Dendritic Cell and Contact Hypersensitivity Responses
por: Chen, Hsin-Chun, et al.
Publicado: (2016)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer
por: Shao, Yiqun, et al.
Publicado: (2017)

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2020)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4anjosfebcken174j2r2fnvtv2